Mechanisms and clinical impact of antifungal drug resistance.

[1]  J. Galgiani,et al.  Antifungal susceptibility testing , 1993, Clinical Microbiology Reviews.

[2]  J. Bodenhoff.  Development of strains of Cryptococcus neoformans resistant to nystatin, amphotericin B, trichomycin and polymyxin B. , 2009, Acta pathologica et microbiologica Scandinavica.

[3]  D. Kerridge,et al.  Uptake of pyrimidines and their derivatives into Candida glabrata and Candida albicans. , 1990, Journal of general microbiology.

[4]  S. Kelly,et al.  Molecular genetic studies on the mode of action of azole antifungal agents. , 1991, Biochemical Society transactions.

[5]  J. Galgiani,et al.  Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies. , 1976, The American journal of medicine.

[6]  W. Merz.  Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance , 1984, Journal of clinical microbiology.

[7]  R. Holt,et al.  MICONAZOLE-RESISTANT CANDIDA , 1978, The Lancet.

[8]  C. Prober,et al.  Prophylactic fluconazole and Candida krusei infections. , 1992, The New England journal of medicine.

[9]  F. Odds.  Resistance of yeasts to azole-derivative antifungals. , 1993, The Journal of antimicrobial chemotherapy.

[10]  P. Nussbaumer,et al.  Squalene Epoxidase Inhibitors: Structural Determinants for Activity and Selectivity of Allylamines and Related Compounds , 1992 .

[11]  A. Polak.  Mode of Action Studies , 1990 .

[12]  P. Marichal,et al.  Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans , 1993, Antimicrobial Agents and Chemotherapy.

[13]  A. Polak.  Synergism of polyene antibiotics with 5-fluorocytosine. , 1978, Chemotherapy.

[14]  D. Shepp,et al.  Comparative Trial of Ketoconazole and Nystatin for Prevention of Fungal Infection in Neutropenic Patients Treated in a Protective Environment , 1985 .

[15]  A. MacGowan,et al.  Prophylactic oral fluconazole and candida fungaemia , 1991, The Lancet.

[16]  P. Troke,et al.  Fluconazole resistance in Candida glabrata , 1993, Antimicrobial Agents and Chemotherapy.

[17]  B. Dupont,et al.  Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole , 1993, Journal of clinical microbiology.

[18]  P. Marichal,et al.  Mechanisms of resistance to azole antifungals. , 1995, Acta biochimica Polonica.

[19]  D. Kerridge,et al.  Pathogenicity of 5-fluorocytosine resistant strains of Candida albicans. , 1990, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[20]  P. Janssen,et al.  Mode of Action of Antifungals of Use in Immunocompromised Patients. Focus on Candida Glabrata and Histoplasma Capsulatum , 1990 .

[21]  M. A. McIlroy.  Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhlitis. , 1991, The Journal of infectious diseases.

[22]  D. Kerridge,et al.  Decreased activity of UMP pyrophosphorylase associated with resistance to 5-fluorocytosine in Candida albicans , 1984, Antimicrobial Agents and Chemotherapy.

[23]  M. Pfaller,et al.  Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis , 1994, Journal of clinical microbiology.

[24]  C. Leen,et al.  Fluconazole resistance in AIDS patients. , 1991, The Journal of antimicrobial chemotherapy.

[25]  K. Holmberg.  In vitro assessment of antifungal drug resistance. , 1986, Acta dermato-venereologica. Supplementum.

[26]  P. Marichal,et al.  Anti-Candida drugs--the biochemical basis for their activity. , 1987, Critical reviews in microbiology.

[27]  W. Merz,et al.  Incidence of polyene-resistant yeasts recovered from clinical specimens , 1980, Antimicrobial Agents and Chemotherapy.

[28]  J. Perfect,et al.  Fluconazole and Candida krusei fungemia. , 1991, The New England journal of medicine.

[29]  G. Sandford,et al.  Isolation and characterization of a polyene-resistant variant of Candida tropicalis , 1979, Journal of clinical microbiology.

[30]  N. Ryder,et al.  Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate , 1986, Antimicrobial Agents and Chemotherapy.

[31]  A. Mallet,et al.  A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole-sensitive and -resistant strains. , 1990, The Journal of applied bacteriology.

[32]  J. F. Ryley,et al.  Azole resistance in Candida albicans. , 1984, Sabouraudia.

[33]  D. Kerridge,et al.  Drug Resistance in Candida albicans and Candida glabrata a , 1988, Annals of the New York Academy of Sciences.

[34]  R. Lehrer,et al.  Development of amphotericin B‐resistant Candida tropicalis in a patient with defective leukocyte function , 1978, The American journal of the medical sciences.

[35]  E. Johnson,et al.  In-vitro resistance to imidazole antifungals in Candida albicans. , 1984, The Journal of antimicrobial chemotherapy.

[36]  G. Milne,et al.  Polyene-Resistant Mutants of Aspergillus fennelliae: Identification of Sterols , 1974, Antimicrobial Agents and Chemotherapy.

[37]  H. I. Winner,et al.  The development of resistance by candida species to polyene antibiotics in vitro. , 1971, Journal of medical microbiology.

[38]  D. Kerridge.  The polyene macrolide antibiotics. , 1979, Postgraduate medical journal.

[39]  D. Stevens,et al.  Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States , 1982, Antimicrobial Agents and Chemotherapy.

[40]  M G Rinaldi,et al.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. , 1991, The New England journal of medicine.

[41]  G. Medoff,et al.  Amphotericin B-induced oxidative damage and killing of Candida albicans. , 1986, The Journal of infectious diseases.

[42]  F. Meunier.  Prevention of Mycoses in Immunocompromised Patients , 1987 .

[43]  M. Grenson,et al.  Evidence for a common transport system for cytosine, adenine and hypoxanthine in Saccharomyces cerevisiae and Candida albicans. , 1973, European journal of biochemistry.

[44]  N. Russell,et al.  The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. , 1986, Journal of general microbiology.

[45]  D. Pappagianis,et al.  Development of Resistance to Amphotericin B in Candida lusitaniae Infecting a Human , 1979, Antimicrobial Agents and Chemotherapy.

[46]  E. Stiehm,et al.  Successful treatment of chronic mucocutaneous candidiasis with ketoconazole. , 1980, The Journal of pediatrics.

[47]  A. Polak,et al.  Antifungal chemotherapy--are we winning? , 1991, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[48]  E. Johnson,et al.  FLUCONAZOLE RESISTANCE IN CANDIDA GLABRATA , 1988, The Lancet.

[49]  E. Johnson,et al.  MODIFIED RESPONSE TO KETOCONAZOLE OF CANDIDA ALBICANS FROM A TREATMENT FAILURE , 1983, The Lancet.

[50]  J. Dekker.  Development of resistance to antifungal agents , 1984 .

[51]  Holt Rj.  Clinical isolates of Canada albicans. , 1979 .

[52]  J. Bodenhoff.  Development of strains of genus Candida and genus Torulopsis resistant to antimycotics. , 1969, Acta pathologica et microbiologica Scandinavica.

[53]  J. Perfect,et al.  Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1 , 1993, Antimicrobial Agents and Chemotherapy.

[54]  K. Barrett-Bee,et al.  The mode of antifungal action of tolnaftate. , 1986, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[55]  A. Orth,et al.  Mode of action of terbinafine in Ustilago maydis and characterization of resistant mutants. , 1990 .

[56]  R. Jund,et al.  Genetic and Physiological Aspects of Resistance to 5-Fluoropyrimidines in Saccharomyces cerevisiae , 1970, Journal of bacteriology.

[57]  C. Kirkpatrick,et al.  Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. , 1983, The American journal of medicine.

[58]  N. Russell,et al.  Inhibition of 14 alpha-sterol demethylase activity in Candida albicans Darlington does not correlate with resistance to azole. , 1987, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[59]  R. Shaw,et al.  Fluorocytosine causes uncoupled dissipation of the proton gradient and behaves as an imperfect substrate of the yeast cytosine permease , 1992, Yeast.

[60]  R. Guinet,et al.  Fatal septicemia due to amphotericin B-resistant Candida lusitaniae , 1983, Journal of clinical microbiology.

[61]  A. Polak.  Virulence of Candida albicans mutants , 1992, Mycoses.

[62]  T. Walsh,et al.  Trichosporon beigelii, an emerging pathogen resistant to amphotericin B , 1990, Journal of clinical microbiology.

[63]  J. Church,et al.  RESISTANCE TO KETOCONAZOLE , 1982, The Lancet.

[64]  W. Lusby,et al.  Sterol content and other characteristics of pimaricin-resistant mutants of Aspergillus nidulans , 1983 .

[65]  R. L. Bennett,et al.  Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans , 1988, Antimicrobial Agents and Chemotherapy.

[66]  A. Polak,et al.  Resistance to Systemic Antifungal Agents , 1984 .

[67]  A. Polak,et al.  Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. , 1982, Chemotherapy.

[68]  D. Kerridge,et al.  Isolation and Characterization of Fluoropyrimidine‐Resistant Mutants in Two Candida Species , 1988, Annals of the New York Academy of Sciences.

[69]  M. Henry,et al.  Mechanism of resistance to terbinafine in two isolates of , 1990 .

[70]  P. Janssen,et al.  Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals. , 1990, Biochemical Society transactions.

[71]  F. Odds,et al.  Characterization of an azole-resistant Candida glabrata isolate , 1992, Antimicrobial Agents and Chemotherapy.

[72]  G. Medoff.  The Mechanism of Action of Amphotericin , 1988 .

[73]  F. Meunier,et al.  Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole. , 1990, Reviews of infectious diseases.

[74]  J. Galgiani,et al.  Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo , 1986, Antimicrobial Agents and Chemotherapy.